DelveInsight projects 47% CAGR for Alport syndrome market through 2036

The research firm said the 7MM market was worth USD 27 million in 2025, with the United States accounting for about 88% as multiple late-stage and mid-stage therapies advance.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.